Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
TipRanks on MSN
Vertex price target lowered to $24 from $30 at BMO Capital
BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $24 from $30 and keeps a Market Perform rating on the ...
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback